Overexpressed in Chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and multiple myeloma (MM).Overexpression of full length and v3 are associated with poorer overall survival and disease progression but more pronounced with v3.RHAMM was identified as an antigenic target with subsequent development of RHAMM-R3 peptide for phase I and II clinical trials. Here, HMMR is linked to acute myeloid leukemia.